secwatch.observer — SEC 8-K summary
======================================

Issuer:     AN2 Therapeutics, Inc. (ANTX)
CIK:        0001880438
Form:       8-K
Filed at:   2024-11-13T23:59:59+00:00
Accession:  0000950170-24-126276
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

AN2 Therapeutics reports Q3 2024 net loss $12.7M, positive Phase 2 epetraborole PRO data in TR-MAC
--------------------------------------------------------------------------------

- Net loss $12.7M in Q3 2024 vs $16.7M in Q3 2023; cash $93.4M, expected to fund operations through 2027.
- Phase 2 portion of EBO-301: epetraborole achieved nominally significant improvements in QOL-B (p=0.0365) and MACrO2 (p=0.0433) vs placebo.
- Company plans to meet FDA in H1 2025 to discuss reinitiating Phase 3 TR-MAC study and top-line Phase 3 data in mid-2025.
- Achieved 50% reduction in expenditures through strategic realignment; R&D expenses decreased to $8.3M from $14.4M.
- Advancing boron chemistry pipeline: Chagas Phase 1 mid-2025, melioidosis Phase 2 enrollment H2 2025, and Gates Foundation grant.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1880438/000095017024126276/0000950170-24-126276-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1880438/000095017024126276/antx-20241113.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-126276

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer